Compare Heron Therapeutics Inc (HRTX) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Synopsys, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $74.04M), while Synopsys, Inc. trades at $502 (market cap $96.33B). The key difference: Synopsys, Inc. is far larger — about 1301.1× Heron Therapeutics Inc's market cap, and Synopsys, Inc. is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Synopsys, Inc. for 71 Days on average.
| HRTX | SNPS | |
|---|---|---|
Market Cap | $74.04M | $96.33B |
Volume | 3,668,095 | 1,631,837 |
Sector | Health | Technology |
52-Week High | $1.49 | $534.56 |
52-Week Low | $0.27 | $367.70 |
Typical Hold Time | 35 Days | 71 Days |
Enterprise Value | $180.78M | $103.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.39, up 17.58% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings performance discussions.
The outlook is mixed: strong analyst support and technical momentum suggest potential upside, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on revenue growth translating to profitability, while key risks include execution challenges and competitive pressures in the biotechnology sector.
Synopsys (SNPS) trades at $497.75, down 1.47% on the day but remains near recent highs following strong quarterly earnings beats and bullish investor sentiment driven by AI partnerships. The stock shows a bullish technical trend with moving averages supporting upside, while RSI levels indicate overbought conditions. Recent news highlights multi-year agreements with OpenAI and Amazon Web Services, fueling growth expectations beyond traditional EDA markets.
The outlook is positive with a consensus price target of $572.54, reflecting 15% upside potential, though high valuation multiples (P/E of 87.73) and integration risks from the Ansys acquisition warrant caution. Revenue growth is projected to accelerate, supported by AI-driven demand, but margin compression and competitive pressures pose medium-term risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
